tuvorlimab

Tuvorlimab is a recombinant humanized IgG1 monoclonal antibody targeting cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), an immune checkpoint molecule that negatively regulates T-cell activation. Developed by Qilu Pharmaceutical, tuvorlimab is produced using the proprietary Mab-Pair technology, which allows for the simultaneous expression of two distinct monoclonal antibodies—tuvorlimab and the PD-1 inhibitor iparomlimab—in a single engineered cell line. This co-formulated product, known as QL1706, is designed to provide dual checkpoint blockade, potentially enhancing anti-tumor immune responses compared to single-agent therapies. Tuvorlimab works by blocking the interaction between CTLA-4 and its ligands, CD80 and CD86, thereby preventing the inhibitory signal and maintaining T-cell activity against malignant cells. It is currently being evaluated in multiple late-stage clinical trials for various solid tumors, including cervical cancer, non-small cell lung cancer, and trophoblastic tumors.

Other names

tuvorlimab